All Comments by Benjamin Wolozin
- Alzheimer's disease: model behaviour.
- Protein kinase C regulation of intracellular and cell surface amyloid precursor protein (APP) cleavage in CHO695 cells.
- Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep.
- Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression.
- Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
- Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain.
- Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease.
- p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction.
- A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
- Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia.
- Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients.
- Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.
- SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.
- Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees.
- Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.